Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation & Amortization (CF) (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $1.1 million as the latest value for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) fell 30.91% year-over-year to $1.1 million; the TTM value through Mar 2026 reached $5.9 million, down 17.24%, while the annual FY2025 figure was $6.4 million, 10.48% down from the prior year.
  • Depreciation & Amortization (CF) hit $1.1 million in Q1 2026 for Bicycle Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q3 2024 and bottomed at $422000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.5 million, with a median of $1.6 million recorded in 2024.
  • Year-over-year, Depreciation & Amortization (CF) surged 275.07% in 2022 and then plummeted 30.91% in 2026.
  • Bicycle Therapeutics' Depreciation & Amortization (CF) stood at $1.4 million in 2022, then increased by 19.34% to $1.7 million in 2023, then grew by 3.02% to $1.7 million in 2024, then dropped by 21.6% to $1.3 million in 2025, then decreased by 15.49% to $1.1 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1.1 million, $1.3 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.